Eli Lilly and

1 day ago · fool.com

Eli Lilly dominates the weight loss drug market and has a strong pipeline that may produce future winners. The company's stock has climbed amid optimism about this portfolio and its impact on earnings growth.

1 day ago · fool.com

Eli Lilly stock has been on a tear, averaging annual gains of more than 30%. Future growth rates may not be quite so high, though.

2 days ago · marketbeat.com

Eli Lilly and Company NYSE: LLY raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound incretin medicines and continued growth across international markets.

2 days ago · 247wallst.com

Mounjaro and Zepbound built Lilly into a trillion-dollar company, but a surge in oncology, immunology, and neuroscience revenue hints that the real growth story is just getting started.

2 days ago · zacks.com

Eli Lilly raises its 2026 revenue outlook as Mounjaro and Zepbound sales surge, Medicare access expands and Foundayo gains traction despite pricing pressures.

3 days ago · seekingalpha.com

Eli Lilly delivered standout 3Q26 results, with 39% revenue growth to $24.4B, driven by Mounjaro and Zepbound franchises. LLY's growth story is increasingly diversified, with Foundayo, Retatrutide, and the Medicare Bridge program offering additional revenue expansion paths. Management raised FY26 revenue guidance by $5.5B, but valuation remains demanding at 37.4x forward earnings and 13.5x forward sales.

3 days ago · seekingalpha.com

Eli Lilly and Company ( LLY ) Q3 2026 Earnings Call October 29, 2026 10:00 AM EDT Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chairman, President & CEO Lucas Montarce - Executive VP & CFO Daniel Skovronsky - Chief Scientific & Product Officer and President of Lilly Research Laboratories Ilya Yuffa - Executive VP and President of Lilly USA & Global Customer Capabilities Carole Ho - Executive VP & President of Lilly Neuroscience Patrik Jonsson - Executive VP & President of Lilly International Kenneth Custer - Executive VP & President of Lilly Cardiometabolic Health Jacob Van Naarden - Executive VP, President of Lilly Oncology & Head of Corporate Business Development Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Steve Scala - TD Cowen, Research Division Terence Flynn - Morgan Stanley, Research Division Trung Huynh - RBC Capital Markets, Research Division Akash Tewari - Jefferies LLC, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Michael Yee - UBS Investment Bank, Research Division Courtney Breen - Bernstein Institutional Services LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Eli Lilly Third Quarter 2026 Earnings Conference Call.

3 days ago · fool.com

Eli Lilly's third-quarter revenue rose 39% to about $24.4 billion, as a 53% jump in volume more than offset a 15% drop in realized prices. Part of the quarter won't repeat, and deal charges are weighing on earnings.

3 days ago · nypost.com

Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.

3 days ago · seekingalpha.com

Eli Lilly and Company delivered solid third-quarter results. In Q3, LLY's non-GAAP EPS and revenue grew by 6.6% and 38.6% year-over-year, respectively. Mounjaro+Zepbound, Lilly's diabetes and obesity treatments, generated $16.08 billion in sales, reflecting 59.1% YoY growth.